secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001628280-22-029606
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Therapeutics sells AVTX-501 milestones and AVTX-007 royalties to ES Therapeutics for $5M
--------------------------------------------------------------------------------

- Closed sale to ES Therapeutics (Armistice affiliate) of rights to milestones from Janssen (AVTX-501) and royalty payments from Apollo (AVTX-007).
- Waived all rights under AVTX-611 license agreement with ES and Armistice.
- Received $5.0M cash payment upon closing on November 10, 2022.
- Board approved under related party policy; Armistice is a significant stockholder.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828022029606/0001628280-22-029606-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828022029606/avtx-20221110.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-029606

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer